Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
37results about How to "Reduce collagen content" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Traditional Chinese medicinal prepn. for treating constipation of slow-remove type, and its prepn. method
InactiveCN1724030AWrigglyPromote peristalsisDigestive systemCapsule deliveryCurative effectTangerine Peel
A Chinese medicine for treating the slow-transmission constipation is prepared from 13 Chinese-medicinal materials including tangerine peel, astragalus root, Chinese angelica root, rehmannia root, etc through proportional mixing, distilling, extracting, concentrating, drying and loading in capsules.
Owner:李红岩
Supermicro Tongxinluo Chinese herbal composite and its new usage
ActiveCN1954825AAvoid damageObvious effectPowder deliveryAnthropod material medical ingredientsVascular endotheliumVentricular remodeling
An application of the Chinese medicine 'Superfine Tongxinluo' in relaxing the vascular endothelial injury caused by atherosclerosis, decreasing the cardiac infarction range after AMI reperfusion, preventing hyperlipemia and atherosclerosis, and treating arteria coronaria spasm, pile, thromboangiitis obliterans, platelet coagulation, etc is disclosed.
Owner:HEBEI YILING MEDICINE INST
Treatment of disease with poly-n-acetylglucosamine nanofibers
InactiveUS20150024014A1Increase contentHigh expressionCosmetic preparationsOrganic active ingredientsFiberDecreased elasticity
Described herein are compositions comprising shortened fibers of poly-N-acetylglucosamine and / or a derivative thereof (“sNAG nanofibers”) and the use of such compositions in the treatment of various diseases, in particular, diseases associated with decreased tensile strength of tissue, decreased elasticity of tissue, increased collagen content or abnormal collagen content in tissue, abnormal alignment of collagen in tissue, and / or increased myofibroblast content in tissue.
Owner:MARINE POLYMER TECH
Medicine composition for treating chronic liver disease
InactiveCN101361782APromote reversalReduce collagen contentOrganic active ingredientsDigestive systemAdditive ingredientChronic hepatitis
Owner:SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
ActiveCN103945695AReduce collagen contentReduce infiltrationBiocideOrganic active ingredientsLactoseLiver fibrosis
Aspects of the invention provide methods for treatment of nonalcoholic steatohepatitis and associated liver fibrosis. In particular, aspects of the invention relate to the use of a therapeutic formulation comprising a galacto-rhamnogalacturonate compound for the treatment of nonalcoholic steatohepatitis and associated liver fibrosis.
Owner:GALECTIN THERAPEUTICS
Drug composition for treating chronic liver disease and its application
ActiveUS20120053135A1Improving liver fibrosis liverImproving liver liver injuryBiocideOrganic active ingredientsAstragalosideDisease
A drug composition for treating chronic liver diseases, consists of: Astragalus Astragalosides and Glycyrrhiza Acid by weight ratio of 3˜6:1. By testing and validating with classic animal model, the results confirmed that the drug composition of the present invention can significantly reduce the collagen content of rat liver, and reduce liver fibrosis and liver injury, wherein the effect is better than the effect of each component alone. The drug composition of the two components or ingredients can improve the anti-hepatic fibrosis, effectively prevent liver fibrosis and promote the development of liver fibrosis reversal, and thus can be used for the treatment and prevention of various chronic hepatitis, liver fibrosis, cirrhosis and other illnesses.
Owner:SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
Traditional Chinese medicine composition used for treating chronic liver diseases
InactiveCN103251876APromote reversalReduce collagen contentDigestive systemAntineoplastic agentsDiseaseChronic hepatitis
The invention discloses a traditional Chinese medicine composition used for treating chronic liver diseases. The composition is composed of the raw medicine materials of, by weight, 6-18 parts of common burreed tuber, 6-18 parts of blue turmeric rhizome, and 9-30 parts of turtle shell. According to the invention, blood-circulation-activating, stasis-removing, hard-mass-softening, and stagnation-eliminating traditional Chinese medicines are used for producing the medicine composition with functions of hepatic fibrosis inhibiting and hepatic damage inhibiting. Classic animal model experiments and validation are carried out. As a result, the traditional Chinese medicine composition provided by the invention assists in substantially reducing model rat liver tissue collagen content, reducing hepatic fibrosis degree and hepatic damage degree, effectively inhibiting hepatic fibrosis development, and promoting hepatic fibrosis reversing. The composition provided by the invention can be used for treating and preventing various diseases such as chronic hepatitis, liver fibrosis, cirrhosis, liver tumor, and the like. The medicine can be prepared into oral solid preparations such as tablets, granules, capsules, and the like.
Owner:SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
Human skin tissue endogenous polypeptide PDHPS1 and application thereof
ActiveCN108623670APrevent proliferationEasy accessPeptide/protein ingredientsCell culture mediaEccentric hypertrophyAlpha sma
The invention discloses a human skin tissue endogenous polypeptide PDHPS1 and an application thereof. The amino acid sequence of the human skin tissue endogenous polypeptide PDHPS1 is shown in SEQ IDNO.1. The polypeptide PDHPS1 inhibits the propagation of a scar dermal fibroblast, inhibits the expression of mRNA of collagen genes COL1A1 and COL1A2 in the scar dermal fibroblast, and obviously reduces the protein expression of a main marker alpha-SMA of a myofibroblast in the scar dermal fibroblast. The human skin tissue endogenous polypeptide PDHPS1 can be used to prepare a drug or agent whichcan inhibit the propagation of the scar dermal fibroblast, reduce the collagen content and reduce the amount of the myofibroblast, and provides a new target spot for inhibiting the scar hypertrophy.
Owner:NANJING MATERNITY & CHILD HEALTH CARE HOSPITAL
Application of JMJD3 inhibitor GSK-J1 HCL to preparation of medicine for treating myocardial fibrosis
PendingCN112641790APlay a regulatory roleReduce collagen contentCardiovascular disorderHeterocyclic compound active ingredientsDiseaseCoronary arteries
The invention belongs to the field of pharmacy, and relates to a new application of a compound GSK-J1 HCL to pharmacy, in particular to an application of a histone demethylase JMJD3 inhibitor GSK-J1 HCL to preparation of a medicine for treating myocardial fibrosis. Through an established myocardial fibrosis model caused by a mouse left coronary artery ligation operation and an Ang II induced NRCFs in-vitro myocardial fibrosis model experiment, a result shows that the GSK-J1 HCL has a regulation and control effect on myocardial fibrosis by inhibiting expression of JMJD3 to reduce collagen content and reducing expression of fibrosis related protein. The compound GSK-J1 HCL (C22H23N5O2.HCL) and the related inhibitor thereof can be used for preparing the medicine for preventing and treating myocardial fibrosis diseases.
Owner:FUDAN UNIV
Melatonin (MT) flexible liposome as well as preparation method and application thereof
ActiveCN111329837ASmall particle sizeSmall PDIOrganic active ingredientsCosmetic preparationsBiophysicsLiposome
The invention belongs to the technical field of medicine and particularly relates to a melatonin (MT) flexible liposome as well as a preparation method and application thereof. The MT flexible liposome is prepared from the following raw materials in parts by weight: 10-30 parts of MT, 70.00-90.00 parts of lecithin, 10-30 parts of cholesterol and 10-30 parts of sodium deoxycholate. The MT flexibleliposome has a better percutaneous permeation effect. Pharmacokinetic experiment results of rats show that the AUC of the flexible liposome is 1.82 times higher than that of ordinary liposome, indicating that the flexible liposome can improve the biocompatibility of percutaneous absorption of the MT. Pharmacodynamic experiment results of mice indicate that the external flexible liposome has an anti-photoaging effect. The flexible liposome enters a human body via skin and changes structures of stratum corneum lipid and keratin and can resist skin injury caused by ultraviolet sunburn.
Owner:SHANDONG FIRST MEDICAL UNIV & SHANDONG ACADEMY OF MEDICAL SCI
Treatment of disease with poly-n-acetylglucosamine nanofibers
InactiveUS20190060348A1Reduce scarsIncrease metabolic rateBiocideCosmetic preparationsDiseaseDecreased elasticity
Described herein are compositions comprising shortened fibers of poly-N-acetylglucosamine and / or a derivative thereof (“sNAG nanofibers”) and the use of such compositions in the treatment of various diseases, in particular, diseases associated with decreased tensile strength of tissue, decreased elasticity of tissue, increased collagen content or abnormal collagen content in tissue, abnormal alignment of collagen in tissue, and / or increased myofibroblast content in tissue.
Owner:MARINE POLYMER TECH
Traditional Chinese medicinal composition for controlling chronic hepatopathy, and uses thereof
InactiveCN103251895AImprove liver functionPromote reversalDigestive systemPlant ingredientsHepatic tumorPinellia
The invention discloses a traditional Chinese medicinal composition for treating the chronic hepatopathy. The composition is prepared through mainly using the following raw medicines, by weight, 9-30 parts of Rhizoma Sparganii, 9-30 parts of Rhizoma Curcumae, 6-30 parts of cortex magnoliae officinalis, 6-30 parts of Cornus officinalis, 1.5-15 parts of Rhizoma Coptidis, 3-30 parts of Radix Aucklandiae, 3-30 parts of dry ginger, 3-15 parts of processed Pinellia Tuber, and 6-30 parts of turtle shell. The medicinal composition having effective hepatic fibrosis and hepatic injury resistances is obtained through adopting traditional Chinese medicines having blood circulation invigorating, blood stasis dispersing, phlegm reducing, hardness softening and bind dissipating effects. Results of classic animal model experiments and verifications prove that the traditional Chinese medicinal composition can substantially reduce the content of collagens in the hepatic tissues of model rats, mitigates the hepatic fibrosis and hepatic injury degrees, and effectively prevents the development of the hepatic fibrosis and promotes the reversion of the hepatic fibrosis. The traditional Chinese medicinal composition can be used for treating and preventing all kinds of chronic hepatitis, hepatic fibrosis, hepatic cirrhosis, hepatic tumors and the like. The traditional Chinese medicinal composition can be processed to prepare oral solid preparations comprising a tablet, a granule, a capsule and the like.
Owner:SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
Human adipose-derived stem cell secreted polypeptide ADSCP2 and application thereof
ActiveCN113817042AReduce collagen contentDecrease mRNA expressionPeptide/protein ingredientsSkeletal/connective tissue cellsMedicinePharmaceutical drug
The invention discloses a human adipose-derived stem cell secreted polypeptide ADSCP2 and an application thereof. The human adipose-derived stem cell secreted polypeptide ADSCP2 has an amino acid sequence as shown in SEQ ID NO. 1. The polypeptide ADSCP2 can inhibit the mRNA expression quantity of collagen genes COL1A1, COL1A2 and COL3A1 in human scar dermal fibroblasts, and the mRNA expression quantity of a main marker ACTA2 of myofibroblasts in the human scar dermal fibroblasts is remarkably reduced. The human adipose-derived stem cell secreted polypeptide ADSCP2 can be used for preparing drugs or reagents for reducing the content of scar dermal fibroblast collagen and reducing the amount of myofibroblasts, and a new target is provided for inhibiting scar hyperplasia.
Owner:NANJING MATERNITY & CHILD HEALTH CARE HOSPITAL
Traditional Chinese medicine composition for treating hepatitis and liver cancer
InactiveCN101612179ASlow drug metabolismLong retention timeOrganic active ingredientsDigestive systemDrugLiver cancer
The invention discloses a traditional Chinese medicine composition for treating hepatitis and liver cancer, comprising the following raw material medicines according to parts by weight: 1 to 120 parts of rhein or rhubarb class substances capable of being metabolized into the rhein in vivo, 1 to 50 parts of quercetin or quercetinic acid glucoside class substances capable of metabolized into the quercetinic acid in vivo and 3 to 60 parts of vinegar radix bupleuri, wherein the rhein is a market-sold product artificially synthesized or naturally extracted, and the purity is more than or equal to 80%. The composition can be prepared into various traditional Chinese medicine preparation medicines which can suppress the multiplication of liver cancer cells and promote the death of the liver cancer cells; an animal experiment validates that compared with the original anticancer medicine, the medicine can greatly enhance the concentration of the medicine in the liver and prolong the detention time of the medicine.
Owner:NO 2 CLINICO MEDICINE COLLEGE GUANGZHOU UNIV OF TRADITIONAL CHINESE MEDICINE
Application of substance for inhibiting phosphorylation of 357 tyrosine residue of YAP protein to prevention of atherosclerosisActiveCN110404072AInhibition formationInhibition of activationOrganic active ingredientsDisease diagnosisSrc inhibitorPhosphorylationThe invention discloses application of a substance for inhibiting phosphorylation of a 357 tyrosine residue of a YAP protein to prevention of atherosclerosis. The substance for inhibiting phosphorylation of the 357 tyrosine residue of the YAP protein is an Src / c-Abl tyrosine kinase double inhibitor or a c-Abl inhibitor or an Src inhibitor; bosutinib is adopted as the Src / c-Abl tyrosine kinase double inhibitor; and experiments prove that the bosutinib prevents atherosclerosis, treats atherosclerosis, decreases the area of plaques of atherosclerosis, reduces lipid deposition, decreases the collagen content, inhibits forming of the plaques of atherosclerosis, inhibits activation of vascular endothelial cells and inhibits the expression level of adherence factors by inhibiting phosphorylation of the 357 tyrosine residue of the YAP protein. The substance has significant application value.Owner:TIANJIN MEDICAL UNIVPharmaceutical composition containing plant extract and application of pharmaceutical composition
ActiveCN113116955APrevent fibrosisReduce collagen contentOrganic active ingredientsMetabolism disorderDiseaseFibrosisThe invention discloses a pharmaceutical composition for preventing, treating and improving metabolic diseases, fibrosis diseases and liver diseases. The composition at least comprises the following two active ingredients: (I) one or more of coleus forskohlii extract, forskolin and isoforskolin; and (II) one or more of a pentacyclic triterpenoid compound and a plant extract containing the pentacyclic triterpenoid compound. Compared with independent use of two components, the pharmaceutical composition disclosed by the invention can achieve a remarkable synergistic effect on prevention and treatment of the metabolic diseases, fibrosis diseases and liver diseases.Owner:CHINA PHARM UNIVSupermicro Tongxinluo Chinese herbal composite and its new usage
ActiveCN1954825BObvious antispasmodic effectEnhanced inhibitory effectPowder deliveryAnthropod material medical ingredientsVascular endotheliumVentricular remodelingAn application of the Chinese medicine 'Superfine Tongxinluo' in relaxing the vascular endothelial injury caused by atherosclerosis, decreasing the cardiac infarction range after AMI reperfusion, preventing hyperlipemia and atherosclerosis, and treating arteria coronaria spasm, pile, thromboangiitis obliterans, platelet coagulation, etc is disclosed.Owner:HEBEI YILING MEDICINE INSTTraditional Chinese medicinal composition for controlling chronic hepatopathy, and uses thereof
InactiveCN103251895BImprove liver functionPromote reversalDigestive systemPlant ingredientsHepatic tumorChronic hepatitisThe invention discloses a traditional Chinese medicinal composition for treating the chronic hepatopathy. The composition is prepared through mainly using the following raw medicines, by weight, 9-30 parts of Rhizoma Sparganii, 9-30 parts of Rhizoma Curcumae, 6-30 parts of cortex magnoliae officinalis, 6-30 parts of Cornus officinalis, 1.5-15 parts of Rhizoma Coptidis, 3-30 parts of Radix Aucklandiae, 3-30 parts of dry ginger, 3-15 parts of processed Pinellia Tuber, and 6-30 parts of turtle shell. The medicinal composition having effective hepatic fibrosis and hepatic injury resistances is obtained through adopting traditional Chinese medicines having blood circulation invigorating, blood stasis dispersing, phlegm reducing, hardness softening and bind dissipating effects. Results of classic animal model experiments and verifications prove that the traditional Chinese medicinal composition can substantially reduce the content of collagens in the hepatic tissues of model rats, mitigates the hepatic fibrosis and hepatic injury degrees, and effectively prevents the development of the hepatic fibrosis and promotes the reversion of the hepatic fibrosis. The traditional Chinese medicinal composition can be used for treating and preventing all kinds of chronic hepatitis, hepatic fibrosis, hepatic cirrhosis, hepatic tumors and the like. The traditional Chinese medicinal composition can be processed to prepare oral solid preparations comprising a tablet, a granule, a capsule and the like.Owner:SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C MLiver-nourishing food-made tea granules for preventing alcohol liver
The invention discloses liver-nourishing food-made tea granules for preventing the alcohol liver, and belongs to the field of nutritional foods. The liver-nourishing food-made tea granulesare made of raw materials including carapace, peach kernel, ginseng leaves, fructus lycii, ligusticum wallichii and the like. The liver-nourishing food-made tea granules have the advantages of capacities of strengthening healthy energy and cultivating origin, reinforcing qi and nourishing blood, promoting blood circulation and dispersing blood stasis, preventing the alcohol liver, and being good and rapid in effect.Owner:BEIJING LVYUAN QIUZHENG SCI & TECH DEVA human skin tissue endogenous polypeptide pdhps1 and its application
ActiveCN108623670BPrevent proliferationEasy accessPeptide/protein ingredientsCell culture mediaEccentric hypertrophyAlpha smaOwner:NANJING MATERNITY & CHILD HEALTH CARE HOSPITALTraditional Chinese medicinal prepn. for treating constipation of slow-remove type, and its prepn. method
InactiveCN100336533CWrigglyPromote peristalsisDigestive systemCapsule deliveryMedicineCurative effectA Chinese medicine for treating the slow-transmission constipation is prepared from 13 Chinese-medicinal materials including tangerine peel, astragalus root, Chinese angelica root, rehmannia root, etc through proportional mixing, distilling, extracting, concentrating, drying and loading in capsules.Owner:李红岩Chinese traditional medicine prescription for treating hepatitis B and preparation technics
ActiveCN100430087CGood liver protectionEnhance the body's immunityDigestive systemAntiviralsForsythiaChinese traditional medicineA Chinese medicine ''Gandening'' in the form of tablet, capsule, or particle for treating hepatitis B is prepared from 6 Chinese-medicinal materials including schisandra fruit, lucid ligustrum fruit, forsythia fruit, zedoary, etc. Its preparing process is also disclosed. Its advantage is high curative rate (82%).Owner:山东世博金都药业有限公司Traditional Chinese medicinal composition for treating chronic obstructive pulmonary diseases
ActiveCN108096242AImprove breathing rateHas the effect of treating chronic obstructive pulmonary diseaseOrganic active ingredientsRespiratory disorderMedicineObstructive Pulmonary DiseasesThe invention provides applications of a bilobalide composition in preparing medicines for preventing / treating chronic obstructive pulmonary diseases. The experiment proves that the bilobalide composition has the efficacies of improving the respiratory rate and pulmonary function of a model rat, reducing the expression of IFN-gamma and IL-6 of a model group rat, increasing the expression of IL-10of the model rat, increasing the number of pulmonary alveoli, reducing the content of collagen, and alleviating the airway remodeling in a dose-dependent manner, so that the effect of treating the chronic obstructive pulmonary diseases is achieved. Therefore, the bilobalide composition has the effect and application value of being prepared into medicines for preventing / treating the chronic obstructive pulmonary diseases.Owner:JIANGSU KANION PHARMA CO LTDApplication of neryl acetate in preparing hypertensive myocardial fibrosis resisting medicine
InactiveCN108524484ALower systolic blood pressureLower diastolic blood pressureEster active ingredientsCardiovascular disorderHypertension medicationsNeryl acetateThe invention discloses application of neryl acetate in preparing a hypertensive myocardial fibrosis resisting medicine. The invention discloses application of ester matter in preparing a hypertensionand / or heart disease resisting medicine and / or health products. A structural formula of the ester matter is shown in description, wherein the R1 is C1 to C3 alkyl, and the R2 and the R3 are hydrogenor C1 to C3 alkyl. The ester matter can reduce body systolic pressure and diastolic pressure to increase cardiac ejection fraction and shortening fraction, reduce a myocardium collagen content and enhance body heart functions, so that a novel selection direction is provided for treating hypertension, heart diseases and hypertensive myocardial fibrosis.Owner:SOUTHERN MEDICAL UNIVERSITYMedicine composition for treating chronic liver disease
InactiveCN101361782BPromote reversalReduce collagen contentOrganic active ingredientsDigestive systemDiseaseAdditive ingredientThe invention pertains to the field of traditional Chinese medicines and relates to a medicine for treating chronic liver diseases. The invention adopts the active ingredients or components in cordyceps polysaccharide, amygdalin and gypenosides with a specific mixture ratio to compose a drug composite with ideal therapeutic effects of resisting hepatic fibrosis and liver injury. By the model tests of classic animals and verification, results confirm that the medicine can remarkably reduce the collagen concentration of the liver tissues of rat models, lighten the degrees of hepatic fibrosis and liver injury and improve the effects of resisting hepatic fibrosis, effectively prevent the development of hepatic fibrosis and promote the reversion of hepatic fibrosis. The effects are better thanthat of individually using each ingredient; the medicine can be used for treating and preventing various diseases, such as chronic hepatitis, hepatic fibrosis, hepatocirrhosis and the like. The medicine can be prepared into oral solid preparations, such as granules, tablets, capsules and the like.Owner:SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C MGalactose‑rhamnose galacturonate composition for treating nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
ActiveCN103945695BReduce collagen contentReduce infiltrationOrganic active ingredientsDigestive systemHepatitisLiver fibrosisAspects of the invention provide methods for treating nonalcoholic steatohepatitis and associated liver fibrosis. In particular, aspects of the invention relate to the use of therapeutic formulations comprising galactose-rhamnogalacturonates for the treatment of non-alcoholic steatohepatitis and associated liver fibrosis.Owner:GALECTIN THERAPEUTICSMedicinal composition for treating chronic hepatopathy, and its application
InactiveCN103127208APromote reversalReduce collagen contentOrganic active ingredientsDigestive systemAstragalosideDiseaseThe invention discloses a medicinal composition for treating chronic hepatopathy. The medicinal composition is composed of astragaloside and glycyrrhizic acid, and the weight ratio of astragaloside to glycyrrhizic acid is 3-6:1. Results of tests and verification through adopting a classic animal model show that the medicinal composition can substantially reduce the collagen content of the hepatic tissue of a model rat, mitigate the hepatic fibrosis degree and the hepatic damage degree, improve the hepatic fibrosis resistance, effectively prevent the development of the hepatic fibrosis and promote the reversion of the hepatic fibrosis, the above effects are better than effects realized through singly using the above components, and the medicinal composition can be used for treating and preventing various diseases comprising chronic hepatitis, hepatic fibrosis, hepatic cirrhosis and the like. The medicinal composition can be processed to prepare oral solid preparations comprising a tablet, a granule, a capsule and the like.Owner:SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M +1Traditional Chinese medicine composition used for treating chronic liver diseases
InactiveCN103251876BPromote reversalReduce collagen contentDigestive systemAntineoplastic agentsDiseaseChronic hepatitisThe invention discloses a traditional Chinese medicine composition used for treating chronic liver diseases. The composition is composed of the raw medicine materials of, by weight, 6-18 parts of common burreed tuber, 6-18 parts of blue turmeric rhizome, and 9-30 parts of turtle shell. According to the invention, blood-circulation-activating, stasis-removing, hard-mass-softening, and stagnation-eliminating traditional Chinese medicines are used for producing the medicine composition with functions of hepatic fibrosis inhibiting and hepatic damage inhibiting. Classic animal model experiments and validation are carried out. As a result, the traditional Chinese medicine composition provided by the invention assists in substantially reducing model rat liver tissue collagen content, reducing hepatic fibrosis degree and hepatic damage degree, effectively inhibiting hepatic fibrosis development, and promoting hepatic fibrosis reversing. The composition provided by the invention can be used for treating and preventing various diseases such as chronic hepatitis, liver fibrosis, cirrhosis, liver tumor, and the like. The medicine can be prepared into oral solid preparations such as tablets, granules, capsules, and the like.Owner:SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C MA kind of human adipose stem cell secreted polypeptide adscp2 and its application
ActiveCN113817042BReduce collagen contentDecrease mRNA expressionPeptide/protein ingredientsSkeletal/connective tissue cellsMedicinePharmaceutical drugOwner:NANJING MATERNITY & CHILD HEALTH CARE HOSPITALTraditional Chinese medicine composition for treating pulmonary interstitial fibrosis and preparation method of traditional Chinese medicine composition
InactiveCN109771559AReduce collagen contentSPIRespiratory disorderLeech/worm material medical ingredientsSemenRadix OphiopogonisThe invention provides a traditional Chinese medicine composition for treating pulmonary interstitial fibrosis. The traditional Chinese medicine composition is prepared from, by weight, 10-20 parts ofradix salviae miltiorrhizae, 4-8 parts of peach kernels, 2-4 parts of leeches, 5-15 parts of radix paeoniae rubra, 5-15 parts of radix ophiopogonis, 5-15 parts of fructus chebulae immaturus and 2-4 parts of semen oroxyli. A corresponding preparation method is adopted. The traditional Chinese medicine composition has the effect of treating the pulmonary interstitial fibrosis.Owner:JIANGSU PROVINCE INST OF TRADITIONAL CHINESE MEDICINE Popular searches
Who we serve- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media Patsnap Eureka Blog Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com
ActiveCN110404072AInhibition formationInhibition of activationOrganic active ingredientsDisease diagnosisSrc inhibitorPhosphorylation
The invention discloses application of a substance for inhibiting phosphorylation of a 357 tyrosine residue of a YAP protein to prevention of atherosclerosis. The substance for inhibiting phosphorylation of the 357 tyrosine residue of the YAP protein is an Src / c-Abl tyrosine kinase double inhibitor or a c-Abl inhibitor or an Src inhibitor; bosutinib is adopted as the Src / c-Abl tyrosine kinase double inhibitor; and experiments prove that the bosutinib prevents atherosclerosis, treats atherosclerosis, decreases the area of plaques of atherosclerosis, reduces lipid deposition, decreases the collagen content, inhibits forming of the plaques of atherosclerosis, inhibits activation of vascular endothelial cells and inhibits the expression level of adherence factors by inhibiting phosphorylation of the 357 tyrosine residue of the YAP protein. The substance has significant application value.
Owner:TIANJIN MEDICAL UNIV
Pharmaceutical composition containing plant extract and application of pharmaceutical composition
ActiveCN113116955APrevent fibrosisReduce collagen contentOrganic active ingredientsMetabolism disorderDiseaseFibrosis
The invention discloses a pharmaceutical composition for preventing, treating and improving metabolic diseases, fibrosis diseases and liver diseases. The composition at least comprises the following two active ingredients: (I) one or more of coleus forskohlii extract, forskolin and isoforskolin; and (II) one or more of a pentacyclic triterpenoid compound and a plant extract containing the pentacyclic triterpenoid compound. Compared with independent use of two components, the pharmaceutical composition disclosed by the invention can achieve a remarkable synergistic effect on prevention and treatment of the metabolic diseases, fibrosis diseases and liver diseases.
Owner:CHINA PHARM UNIV
Supermicro Tongxinluo Chinese herbal composite and its new usage
ActiveCN1954825BObvious antispasmodic effectEnhanced inhibitory effectPowder deliveryAnthropod material medical ingredientsVascular endotheliumVentricular remodeling
An application of the Chinese medicine 'Superfine Tongxinluo' in relaxing the vascular endothelial injury caused by atherosclerosis, decreasing the cardiac infarction range after AMI reperfusion, preventing hyperlipemia and atherosclerosis, and treating arteria coronaria spasm, pile, thromboangiitis obliterans, platelet coagulation, etc is disclosed.
Owner:HEBEI YILING MEDICINE INST
Traditional Chinese medicinal composition for controlling chronic hepatopathy, and uses thereof
InactiveCN103251895BImprove liver functionPromote reversalDigestive systemPlant ingredientsHepatic tumorChronic hepatitis
The invention discloses a traditional Chinese medicinal composition for treating the chronic hepatopathy. The composition is prepared through mainly using the following raw medicines, by weight, 9-30 parts of Rhizoma Sparganii, 9-30 parts of Rhizoma Curcumae, 6-30 parts of cortex magnoliae officinalis, 6-30 parts of Cornus officinalis, 1.5-15 parts of Rhizoma Coptidis, 3-30 parts of Radix Aucklandiae, 3-30 parts of dry ginger, 3-15 parts of processed Pinellia Tuber, and 6-30 parts of turtle shell. The medicinal composition having effective hepatic fibrosis and hepatic injury resistances is obtained through adopting traditional Chinese medicines having blood circulation invigorating, blood stasis dispersing, phlegm reducing, hardness softening and bind dissipating effects. Results of classic animal model experiments and verifications prove that the traditional Chinese medicinal composition can substantially reduce the content of collagens in the hepatic tissues of model rats, mitigates the hepatic fibrosis and hepatic injury degrees, and effectively prevents the development of the hepatic fibrosis and promotes the reversion of the hepatic fibrosis. The traditional Chinese medicinal composition can be used for treating and preventing all kinds of chronic hepatitis, hepatic fibrosis, hepatic cirrhosis, hepatic tumors and the like. The traditional Chinese medicinal composition can be processed to prepare oral solid preparations comprising a tablet, a granule, a capsule and the like.
Owner:SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
Liver-nourishing food-made tea granules for preventing alcohol liver
The invention discloses liver-nourishing food-made tea granules for preventing the alcohol liver, and belongs to the field of nutritional foods. The liver-nourishing food-made tea granulesare made of raw materials including carapace, peach kernel, ginseng leaves, fructus lycii, ligusticum wallichii and the like. The liver-nourishing food-made tea granules have the advantages of capacities of strengthening healthy energy and cultivating origin, reinforcing qi and nourishing blood, promoting blood circulation and dispersing blood stasis, preventing the alcohol liver, and being good and rapid in effect.
Owner:BEIJING LVYUAN QIUZHENG SCI & TECH DEV
A human skin tissue endogenous polypeptide pdhps1 and its application
ActiveCN108623670BPrevent proliferationEasy accessPeptide/protein ingredientsCell culture mediaEccentric hypertrophyAlpha sma
Owner:NANJING MATERNITY & CHILD HEALTH CARE HOSPITAL
Traditional Chinese medicinal prepn. for treating constipation of slow-remove type, and its prepn. method
InactiveCN100336533CWrigglyPromote peristalsisDigestive systemCapsule deliveryMedicineCurative effect
A Chinese medicine for treating the slow-transmission constipation is prepared from 13 Chinese-medicinal materials including tangerine peel, astragalus root, Chinese angelica root, rehmannia root, etc through proportional mixing, distilling, extracting, concentrating, drying and loading in capsules.
Owner:李红岩
Chinese traditional medicine prescription for treating hepatitis B and preparation technics
ActiveCN100430087CGood liver protectionEnhance the body's immunityDigestive systemAntiviralsForsythiaChinese traditional medicine
A Chinese medicine ''Gandening'' in the form of tablet, capsule, or particle for treating hepatitis B is prepared from 6 Chinese-medicinal materials including schisandra fruit, lucid ligustrum fruit, forsythia fruit, zedoary, etc. Its preparing process is also disclosed. Its advantage is high curative rate (82%).
Owner:山东世博金都药业有限公司
Traditional Chinese medicinal composition for treating chronic obstructive pulmonary diseases
ActiveCN108096242AImprove breathing rateHas the effect of treating chronic obstructive pulmonary diseaseOrganic active ingredientsRespiratory disorderMedicineObstructive Pulmonary Diseases
The invention provides applications of a bilobalide composition in preparing medicines for preventing / treating chronic obstructive pulmonary diseases. The experiment proves that the bilobalide composition has the efficacies of improving the respiratory rate and pulmonary function of a model rat, reducing the expression of IFN-gamma and IL-6 of a model group rat, increasing the expression of IL-10of the model rat, increasing the number of pulmonary alveoli, reducing the content of collagen, and alleviating the airway remodeling in a dose-dependent manner, so that the effect of treating the chronic obstructive pulmonary diseases is achieved. Therefore, the bilobalide composition has the effect and application value of being prepared into medicines for preventing / treating the chronic obstructive pulmonary diseases.
Owner:JIANGSU KANION PHARMA CO LTD
Application of neryl acetate in preparing hypertensive myocardial fibrosis resisting medicine
InactiveCN108524484ALower systolic blood pressureLower diastolic blood pressureEster active ingredientsCardiovascular disorderHypertension medicationsNeryl acetate
The invention discloses application of neryl acetate in preparing a hypertensive myocardial fibrosis resisting medicine. The invention discloses application of ester matter in preparing a hypertensionand / or heart disease resisting medicine and / or health products. A structural formula of the ester matter is shown in description, wherein the R1 is C1 to C3 alkyl, and the R2 and the R3 are hydrogenor C1 to C3 alkyl. The ester matter can reduce body systolic pressure and diastolic pressure to increase cardiac ejection fraction and shortening fraction, reduce a myocardium collagen content and enhance body heart functions, so that a novel selection direction is provided for treating hypertension, heart diseases and hypertensive myocardial fibrosis.
Owner:SOUTHERN MEDICAL UNIVERSITY
Medicine composition for treating chronic liver disease
InactiveCN101361782BPromote reversalReduce collagen contentOrganic active ingredientsDigestive systemDiseaseAdditive ingredient
The invention pertains to the field of traditional Chinese medicines and relates to a medicine for treating chronic liver diseases. The invention adopts the active ingredients or components in cordyceps polysaccharide, amygdalin and gypenosides with a specific mixture ratio to compose a drug composite with ideal therapeutic effects of resisting hepatic fibrosis and liver injury. By the model tests of classic animals and verification, results confirm that the medicine can remarkably reduce the collagen concentration of the liver tissues of rat models, lighten the degrees of hepatic fibrosis and liver injury and improve the effects of resisting hepatic fibrosis, effectively prevent the development of hepatic fibrosis and promote the reversion of hepatic fibrosis. The effects are better thanthat of individually using each ingredient; the medicine can be used for treating and preventing various diseases, such as chronic hepatitis, hepatic fibrosis, hepatocirrhosis and the like. The medicine can be prepared into oral solid preparations, such as granules, tablets, capsules and the like.
Owner:SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
Galactose‑rhamnose galacturonate composition for treating nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
ActiveCN103945695BReduce collagen contentReduce infiltrationOrganic active ingredientsDigestive systemHepatitisLiver fibrosis
Aspects of the invention provide methods for treating nonalcoholic steatohepatitis and associated liver fibrosis. In particular, aspects of the invention relate to the use of therapeutic formulations comprising galactose-rhamnogalacturonates for the treatment of non-alcoholic steatohepatitis and associated liver fibrosis.
Owner:GALECTIN THERAPEUTICS
Medicinal composition for treating chronic hepatopathy, and its application
InactiveCN103127208APromote reversalReduce collagen contentOrganic active ingredientsDigestive systemAstragalosideDisease
The invention discloses a medicinal composition for treating chronic hepatopathy. The medicinal composition is composed of astragaloside and glycyrrhizic acid, and the weight ratio of astragaloside to glycyrrhizic acid is 3-6:1. Results of tests and verification through adopting a classic animal model show that the medicinal composition can substantially reduce the collagen content of the hepatic tissue of a model rat, mitigate the hepatic fibrosis degree and the hepatic damage degree, improve the hepatic fibrosis resistance, effectively prevent the development of the hepatic fibrosis and promote the reversion of the hepatic fibrosis, the above effects are better than effects realized through singly using the above components, and the medicinal composition can be used for treating and preventing various diseases comprising chronic hepatitis, hepatic fibrosis, hepatic cirrhosis and the like. The medicinal composition can be processed to prepare oral solid preparations comprising a tablet, a granule, a capsule and the like.
Owner:SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M +1
Traditional Chinese medicine composition used for treating chronic liver diseases
InactiveCN103251876BPromote reversalReduce collagen contentDigestive systemAntineoplastic agentsDiseaseChronic hepatitis
The invention discloses a traditional Chinese medicine composition used for treating chronic liver diseases. The composition is composed of the raw medicine materials of, by weight, 6-18 parts of common burreed tuber, 6-18 parts of blue turmeric rhizome, and 9-30 parts of turtle shell. According to the invention, blood-circulation-activating, stasis-removing, hard-mass-softening, and stagnation-eliminating traditional Chinese medicines are used for producing the medicine composition with functions of hepatic fibrosis inhibiting and hepatic damage inhibiting. Classic animal model experiments and validation are carried out. As a result, the traditional Chinese medicine composition provided by the invention assists in substantially reducing model rat liver tissue collagen content, reducing hepatic fibrosis degree and hepatic damage degree, effectively inhibiting hepatic fibrosis development, and promoting hepatic fibrosis reversing. The composition provided by the invention can be used for treating and preventing various diseases such as chronic hepatitis, liver fibrosis, cirrhosis, liver tumor, and the like. The medicine can be prepared into oral solid preparations such as tablets, granules, capsules, and the like.
Owner:SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
A kind of human adipose stem cell secreted polypeptide adscp2 and its application
ActiveCN113817042BReduce collagen contentDecrease mRNA expressionPeptide/protein ingredientsSkeletal/connective tissue cellsMedicinePharmaceutical drug
Owner:NANJING MATERNITY & CHILD HEALTH CARE HOSPITAL
Traditional Chinese medicine composition for treating pulmonary interstitial fibrosis and preparation method of traditional Chinese medicine composition
InactiveCN109771559AReduce collagen contentSPIRespiratory disorderLeech/worm material medical ingredientsSemenRadix Ophiopogonis
The invention provides a traditional Chinese medicine composition for treating pulmonary interstitial fibrosis. The traditional Chinese medicine composition is prepared from, by weight, 10-20 parts ofradix salviae miltiorrhizae, 4-8 parts of peach kernels, 2-4 parts of leeches, 5-15 parts of radix paeoniae rubra, 5-15 parts of radix ophiopogonis, 5-15 parts of fructus chebulae immaturus and 2-4 parts of semen oroxyli. A corresponding preparation method is adopted. The traditional Chinese medicine composition has the effect of treating the pulmonary interstitial fibrosis.
Owner:JIANGSU PROVINCE INST OF TRADITIONAL CHINESE MEDICINE
Popular searches
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com